[1]方丽英,黄宝宇,黄敏丽.Ozurdex与康柏西普治疗视网膜静脉阻塞继发黄斑水肿的疗效对比[J].眼科新进展,2021,41(3):231-235.[doi:10.13389/j.cnki.rao.2021.0048]
　FANG Liying,HUANG Baoyu,HUANG Minli.Comparison of the curative effect of Ozurdex and conbercept in the treatment of macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2021,41(3):231-235.[doi:10.13389/j.cnki.rao.2021.0048]
点击复制

Ozurdex与康柏西普治疗视网膜静脉阻塞继发黄斑水肿的疗效对比/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
41卷
期数:
2021年3期
页码:
231-235
栏目:
应用研究
出版日期:
2021-03-05

文章信息/Info

Title:
Comparison of the curative effect of Ozurdex and conbercept in the treatment of macular edema secondary to retinal vein occlusion
作者:
方丽英; 黄宝宇; 黄敏丽
530021　广西壮族自治区南宁市，广西医科大学第一附属医院眼科
Author(s):
FANG Liying; HUANG Baoyu; HUANG Minli
Department of Ophthalmology,the First Affiliated Hospital of Guangxi Medical University,Nanning 530021,Guangxi Zhuang Autonomous Region,China
关键词:
视网膜静脉阻塞; 黄斑水肿; 康柏西普; Ozurdex
Keywords:
retinal vein occlusion;  macular edema;  conbercept;  Ozurdex
分类号:
R774
DOI:
10.13389/j.cnki.rao.2021.0048
文献标志码:
A
摘要:
目的　对比分析Ozurdex与康柏西普治疗视网膜静脉阻塞继发黄斑水肿（RVO-ME）的临床疗效。方法　选取2018年2月至2020年5月就诊于我院，并经荧光素眼底血管造影（FFA）、光学相干断层扫描（OCT）检查确诊的RVO-ME患者44例44眼，22例患者选择Ozurdex治疗（Ozurdex组），22例患者选择康柏西普治疗（康柏西普组），所有患者均进行玻璃体内注药。对比并分析两组患者治疗前和治疗后1个月、2个月、3个月、4个月、6个月、12个月的最佳矫正视力（BCVA）、黄斑中心凹视网膜厚度（CMT）、眼压、眼前段及眼底情况等变化，以及可能出现的并发症。结果　Ozurdex组和康柏西普组患者治疗后1个月、2个月、3个月、4个月、6个月、12个月的BCVA及CMT与治疗前相比，差异均有统计学意义（均为P<0.05）。Ozurdex组和康柏西普组治疗后不同时间点BCVA及CMT比较，差异均无统计学意义（均为P>0.05）。Ozurdex组患者玻璃体内注射次数为（2.09±0.68）次，康柏西普组为（5.14±1.21）次，差异有统计学意义（P<0.05）。两组患者治疗后不同时间点眼压与治疗前比较，差异均无统计学意义（均为P>0.05）；两组患者术后均未发生眼内炎、视网膜脱离等不良反应。结论　Ozurdex和康柏西普玻璃体内注射均可有效改善RVO-ME患者视功能及降低CMT，但Ozurdex疗效持续时间较长，注射次数较少。
Abstract:
Objective　To explore the comparison of clinical efficacy of Ozurdex and Conbercept in the treatment of macular edema secondary to retinal vein occlusion (RVO-ME).Methods　A total of 44 patients with 44 eyes of RVO-ME who were diagnosed by fundus fluorescein angiography (FFA) and optical coherence tomography (OCT) from February 2018 to May 2020 were selected for treatment in our hospital, of whom 22 patients chose Ozurdex treatment (Ozurdex group), and 22 patients chose conbercept treatment (conbercept group), and all patients received intravitreal injection. The changes of best corrected visual acuity (BCVA), macular fovea retinal thickness (CMT), ocular pressure, anterior segment and fundus conditions, as well as possible complications, were compared and analyzed before treatment and 1 month, 2 months, 3 months, 4 months, 6 months and 12 months after treatment.Results　Compared with those before treatment, the differences in BCVA and CMT of patients in the Ozurdex group and the conbercept group were statistically significant at 1 month, 2 months, 3 months, 4 months, 6 months, and 12 months after treatment (all P<0.05). There was no statistically significant difference in BCVA and CMT between the Ozurdex group and the conbercept group at different time points after treatment (all P>0.05). The number of intravitreal injections in the Ozurdex group was (2.09±0.68) times, and the number of intravitreal injections in the conbercept group was (5.14±1.21) times, and the difference was statistically significant (P<0.05). There was no significant difference in intraocular pressure between the two groups of patients at different time points after treatment and before treatment (all P>0.05). There were no adverse reactions such as endophthalmitis and retinal detachment in the two groups.Conclusion　Both Ozurdex and conbercept intravitreal injection can effectively improve the visual function and reduce CMT in patients with RVO-ME, but Ozurdex has a longer duration of efficacy and fewer injections.

参考文献/References:

［1］　SCOTT I U,VANVELDHUISEN P C,IP M S,BLODI B A,ODEN N L,AWH C C,et al.Effect of Bevacizumab vs aflibercept on visual acuity among patients with macular edema due to central retinal vein occlusion:the score2 randomized clinical trial ［J］.JAMA,2017,317(20):2072-2087.
［2］　CAMPOCHIARO P A,HAFIZ G,SHAH S M,NGUYEN Q D,YING H,DO D V,et al.Ranibizumab for macular edema due to retinal vein occlusions:implication of VEGF as a critical stimulator ［J］.Mol Ther,2008,16(4):791-799.
［3］　KOSS M J,PFISTER M,ROTHWEILER F,MICHAELIS M,CINATL J,SCHUBERT R,et al.Comparison of cytokine levels from undiluted vitreous of untreated patients with retinal vein occlusion ［J］.Acta Ophthalmol,2012,90(2):e98-e103.
［4］　EHLERS J P,FEKRAT S.Retinal vein occlusion:beyond the acute event ［J］.Surv Ophthalmol,2011,56(4):281-299.
［5］　MARNEROS A G,FAN J,YOKOYAMA Y,GERBER H P,FERRARA N,CROUCH R K,et al.Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function ［J］.Am J Pathol,2005,167(5):1451-1459.
［6］　JAULIM A,AHMED B,KHANAM T,CHATZIRALLI I P.Branch retinal vein occlusion:epidemiology,pathogenesis,risk factors,clinical features,diagnosis,and complications.An update of the literature ［J］.Retina,2013,33(5):901-910.
［7］　NOMA H,FUNATSU H,MIMURA T,EGUCHI S.Vascular endothelial growth factor receptor-2 in macular oedema with retinal vein occlusion ［J］.Ophthalmic Res,2012,48(1):56-58.
［8］　NOMA H,MIMURA T,YASUDA K,SHIMURA M.Role of soluble vascular endothelial growth factor receptors-1 and -2,their ligands,and other factors in branch retinal vein occlusion with macular edema ［J］.Invest Ophthalmol Vis Sci,2014,55(6):3878-3885.
［9］　REHAK M,WIEDEMANN P.Retinal vein thrombosis:pathogenesis and management ［J］.J Thromb Haemost,2010,8(9):1886-1894.
［10］　ROGERS S,MCINTOSH R L,CHEUNG N,LIM L,WANG J J,MITCHELL P,et al.The prevalence of retinal vein occlusion:pooled data from population studies from the United States,Europe,Asia,and Australia ［J］.Ophthalmology,2010,117(2):313-319.
［11］　陈婷,朱登峰,杨玲.视网膜光凝联合雷珠单抗或康柏西普对RVO继发ME的疗效 ［J］.国际眼科杂志,2018,18(9):1594-1598.
CHEN T，ZHU D F，YANG L.Efficacy of retinal photocoagulation combined with ranibizumab or conbercept in patients with macular edema secondary to retinal vein occlusion ［J］.Int Eye Sci,2018,18(9):1594-1598.
［12］　HEIER J S,CAMPOCHIARO P A,YAU L,LI Z,SAROJ N,RUBIO R G,et al.Ranibizumab for macular edema due to retinal vein occlusions:long-term follow-up in the HORIZON trial ［J］.Ophthalmology,2012,119(4):802-809.
［13］　GARAY-ARAMBURU G,GMEZ-MORENO .A 5-year follow-up study of the treatment of macular edema due to retinal vein occlusion using dexamethasone intravitreal implants ［J］.J Ocul Pharmacol Ther,2018,34(6):436-441.
［14］　KONIDARIS V E,TSAOUSIS K T,ANZIDEI R,De LA MATA G,BRENT A J.Real-world results of switching treatment from ranibizumab to aflibercept in macular oedema secondary to branch retinal vein occlusion ［J］.Ophthalmol Ther,2018,7(2):387-395.
［15］　FENG J,ZHAO T,ZHANG Y,MA Y,JIANG Y.Differences in aqueous concentrations of cytokines in macular edema secondary to branch and central retinal vein occlusion ［J］.PLoS One,2013,8(7):e68149.
［16］　CAKIR M,DOGAN M,BAYRAKTAR Z,BAYRAKTAR S,ACAR N,ALTAN T,et al.Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation ［J］.Retina,2008,28(3):465-472.
［17］　MOISSEIEV E,GOLDSTEIN M,WAISBOURD M,BARAK A,LOEWENSTEIN A.Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion ［J］.Eye,2013,27(1):65-71.
［18］　CHIQUET C,DUPUY C,BRON A M,APTEL F,STRAUB M,ISAICO R,et al.Intravitreal dexamethasone implant versus anti-VEGF injection for treatment-naive patients with retinal vein occlusion and macular edema:a 12-month follow-up study ［J］.Graefes Arch Clin Exp Ophthalmol,2015,253(12):2095-2102.
［19］　梁婉玲,周怀胜,马海智,卢彦,晏世刚.地塞米松玻璃体内植入剂Ozurdex治疗视网膜静脉阻塞继发黄斑水肿的短期疗效 ［J］.眼科新进展,2019,39(7):666-669.
LIANG W L,ZHOU H S,MA H Z,LU Y,YAN S G.The short-term effect of dexamethasone intravitreal implant Ozurdex in the treatment of macular edema secondary to retinal vein occlusion［J］.Rec Adv Ophthalmol,2019,39(7):666-669.
［20］　SUN Z,ZHOU H,LIN B,JIAO X,LUO Y,ZHANG F,et al.Efficacy and safety of intravitreal conbercept injections in macular edema secondary to retinal vein occlusion ［J］.Retina,2017,37(9):1723-1730.
［21］　ZENG H Y,LIU Q,LI X X,SUN Y X,ZHANG Z J.One-year efficacy of intravitreal conbercept injection for macular oedema secondary to central retinal vein occlusion in Chinese patients ［J］.Eye,2020,34(8):1459-1464.
［22］　冼志林,梁琦晨,袁洋行,黄金飞,王珂鳗,翁宏武,等.地塞米松玻璃体内植入剂Ozurdex治疗视网膜静脉阻塞继发黄斑水肿的研究进展 ［J］.眼科新进展,2020,40(3):296-300.
XIAN Z L,LIANG Q C,YUAN Y X,HUANG J F,WANG K W,WENG H W,et al.Research progress of dexamethasone intravitreal implant Ozurdex in the treatment of macular edema secondary to retinal vein occlusion ［J］.Rec Adv Ophthalmol,2020,40(3):296-300.
［23］　HALLER J A,BANDELLO F,BELFORT R Jr,BLUMENKRANZ M S,GILLIES M,HEIER J,et al.Randomized,sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion ［J］.Ophthalmology,2010,117(6):1134-1146.
［24］　HOERAUF H,FELTGEN N,WEISS C,PAULUS E M,SCHMITZ-VALCKENBERG S,PIELEN A,et al.Clinical efficacy and safety of ranibizumab versus dexamethasone for central retinal vein occlusion (COMRADE C):A European Label Study ［J］.Am J Ophthalmol,2016,169:258-267.
［25］　谷潇雅,戴虹,喻晓兵.地塞米松玻璃体腔植入剂治疗视网膜静脉阻塞继发黄斑水肿一年临床观察 ［J］.中华眼底病杂志,2018,34(3):221-227.
GU X Y,DAI H,YU X B.A one-year clinical observation of dexamethasone vitreous implant in the treatment of macular edema secondary to retinal vein occlusion ［J］.Chin J Ocul Fundus Dis,2018,34(3):221-227.
［26］　黎晓新,王宁利,梁小玲,徐格致,Xiao-yan Li,Jenny Jiao,等.地塞米松玻璃体腔植入剂治疗中国患者视网膜静脉阻塞继发黄斑水肿的安全性和有效性:随机、假注射对照、多中心研究 ［J］.中华眼底病杂志,2018,34(3):212-220.
LI X X,WANG N L,LIANG X L,XU G Z,LI X Y,JIAO J，et al.Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients:randomized,sham-controlled,multicenter study ［J］.Chin J Ocul Fundus Dis,2018,34(3):212-220.
［27］　HALLER J A,BANDELLO F,BELFORT R Jr,BLUMENKRANZ M S,GILLIES M,HEIER J,et al.Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results ［J］.Ophthalmology,2011,118(12):2453-2460.
［28］　GADO A S,MACKY T A.Dexamethasone intravitreous implant versus bevacizumab for central retinal vein occlusion-related macular oedema:a prospective randomized comparison ［J］.Clin Exp Ophthalmol,2014,42(7):650-655.
［29］　MAYER W J,HADJIGOLI A,WOLF A,HEROLD T,HARITOGLOU C.Comparison of intravitreal dexamethasone implant versus intravitreal ranibizumab as a first-line treatment of macular oedema due to retinal vein occlusion ［J］.KlinMonbl Augenheilkd,2015,232(11):1289-1296.
［30］　BANDELLO F,AUGUSTIN A,TUFAIL A,LEABACK R.A 12-month,multicenter,parallel group comparison of dexamethasone intravitreal implant versus ranibizumab in branch retinal vein occlusion ［J］.Eur J Ophthalmol,2018,28(6):697-705.
［31］　CHATZIRALLI I,THEODOSSIADIS G,KABANAROU S A,PARIKAKIS E,XIROU T,MITROPOULOS P,et al.Ranibizumab versus dexamethasone implant for central retinal vein occlusion:the RANIDEX study ［J］.Graefes Arch Clin Exp Ophthalmol,2017,255(10):1899-1905.
［32］　PIELEN A,BHLER A D,HEINZELMANN S U,BHRINGER D,NESS T,JUNKER B.Switch of intravitreal therapy for macular edema secondary to retinal vein occlusion from anti-vegf to dexamethasone implant and vice versa ［J］.J Ophthalmol,2017,2017:5831682.

相似文献/References:

[1]王刚.曲安奈德联合氪激光治疗视网膜静脉阻塞的临床疗效观察[J].眼科新进展,2013,33(7):000.
[2]马宇 刘意 郭娟 周利晓.金纳多联合血栓通对视网膜静脉阻塞患者同型半胱氨酸水平的影响[J].眼科新进展,2013,33(9):000.
[3]李国兴 韩丽英.曲安奈德玻璃体腔注射治疗黄斑水肿[J].眼科新进展,2008,28(9):000.
[4]袁子茗 王帅 宋蓓雯 胡健艳 吴强.维速达尔光动力疗法诱导兔视网膜静脉阻塞的实验研究[J].眼科新进展,2012,32(9):000.
[5]周正申 孙静芬.白内障超声乳化术后黄斑区光学相干断层扫描观察[J].眼科新进展,2013,33(2):000.
[6]刘广峰 蔺洁 范颖 顾铮 高新晓 朱岩 孟忻 王华 贾宇颂 付秀稳 汪军.非增生型糖尿病视网膜病变黄斑水肿患者黄斑区谱域光学相干断层扫描中高反射信号的特征分析[J].眼科新进展,2013,33(4):000.
[7]鲁丹 王康 王艳玲 林鹏耀 李茜 李明铭.后Tenon囊下注射曲安奈德辅助全视网膜光凝治疗糖尿病视网膜病变[J].眼科新进展,2013,33(5):000.
[8]李娟娟 李燕.先天性及获得性视盘血管袢的临床观察[J].眼科新进展,2013,33(11):000.
[9]张祺 冯劼 李培凤 金翼.Lucentis联合氪黄激光治疗视网膜分支静脉阻塞黄斑水肿的疗效观察[J].眼科新进展,2013,33(12):000.
[10]徐斌 戴奕娟 梁丽 杨露. 传统格栅样激光与577nm黄色微脉冲激光光凝治疗黄斑水肿疗效对比[J].眼科新进展,2014,34(2):181.
[11]陆秉文 吴星伟.视网膜静脉阻塞黄斑水肿患者玻璃体内注射ranibi-zumab后视野变化[J].眼科新进展,2013,33(12):000.
[12]金昱,石安娜,刘淼. 玻璃体内注射雷珠单抗（Ranibizumab）治疗视网膜静脉阻塞继发黄斑水肿[J].眼科新进展,2014,34(9):855.[doi:10.13389/j.cnki.rao.2014.0236]
[13]周洁,王宏彬,王文亭.雷珠单抗治疗视网膜静脉阻塞的临床研究[J].眼科新进展,2016,36(1):070.[doi:10.13389/j.cnki.rao.2016.0020]
　ZHOU Jie,WANG Hong-Bin,WANG Wen-Ting.Efficacy of intravitreal injection of ranibizumab for retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(3):070.[doi:10.13389/j.cnki.rao.2016.0020]
[14]王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471.[doi:10.13389/j.cnki.rao.2016.0126]
　WANG Chen,LI Dong-Hao,WEN Yi-Yi.Intravitreal injection of conbercept combined with selective peripheral retinal photocoagulation for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(3):471.[doi:10.13389/j.cnki.rao.2016.0126]
[15]张敏,朱健华,冯浩,等.视网膜静脉阻塞合并黄斑水肿患者黄斑区微结构改变与视力的相关性分析[J].眼科新进展,2016,36(11):1061.[doi:10.13389/j.cnki.rao.2016.0283]
　ZHANG Min,ZHU Jian-Hua,FENG Hao,et al.Macular microstructure changes in retinal vein occlusion and its correlation with visual acuity[J].Recent Advances in Ophthalmology,2016,36(3):1061.[doi:10.13389/j.cnki.rao.2016.0283]
[16]夏松,陈有信.视网膜静脉阻塞继发黄斑水肿的抗VEGF药物治疗进展[J].眼科新进展,2016,36(11):1093.[doi:10.13389/j.cnki.rao.2016.0292]
　XIA Song,CHEN You-Xin.Research progress on anti-VEGF drugs for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(3):1093.[doi:10.13389/j.cnki.rao.2016.0292]
[17]马为梅,雷晓琴,田芳,等.视网膜静脉阻塞黄斑水肿的多焦视网膜电图与光学相干断层扫描分析[J].眼科新进展,2017,37(7):651.[doi:10.13389/j.cnki.rao.2017.0165]
　MA Wei-Mei,LEI Xiao-Qin,TIAN Fang,et al.Multifocal electroretinogram and optical coherence tomography characteristics of macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2017,37(3):651.[doi:10.13389/j.cnki.rao.2017.0165]
[18]李筱荣,周怀蔚.重视黄斑水肿的病因、治疗及预防[J].眼科新进展,2019,39(7):601.[doi:10.13389/j.cnki.rao.2019.0139]
　LI Xiao-Rong,ZHOU Huai-Yu.Special attention to the cause,treatment and prevention of macular edema[J].Recent Advances in Ophthalmology,2019,39(3):601.[doi:10.13389/j.cnki.rao.2019.0139]
[19]梁婉玲,周怀胜,马海智,等.地塞米松玻璃体内植入剂Ozurdex治疗视网膜静脉阻塞继发黄斑水肿的短期疗效[J].眼科新进展,2019,39(7):666.[doi:10.13389/j.cnki.rao.2019.0153]
　LIANG Wan-Ling,ZHOU Huai-Sheng,MA Hai-Zhi,et al.The short-term efficacy of Ozurdex for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2019,39(3):666.[doi:10.13389/j.cnki.rao.2019.0153]
[20]栗怡然,朱瑞琳,杨柳.炎症在视网膜静脉阻塞性黄斑水肿中的作用[J].眼科新进展,2020,40(1):090.[doi:10.13389/j.cnki.rao.2020.0023]
　LI Yiran,ZHU Ruilin,YANG Liu.Role of inflammation in macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2020,40(3):090.[doi:10.13389/j.cnki.rao.2020.0023]

备注/Memo

备注/Memo:
广西壮族自治区卫生和计划生育委员会自筹经费科研课题（编号：Z20180945）；广西自然科学基金项目（编号：2014GXNSFAA118273）；广西教育厅高校科研项目（编号：YB2014072）
更新日期/Last Update: 2021-03-05